TSPAN4: A novel drug target and biomarker for treating spasticity and other neurodegenerative disorders

Target Name: TSPAN4

NCBI ID: G7106

TSPAN4

TSPAN4: A novel drug target and biomarker for treating spasticity and other neurodegenerative disorders

Abstract:
Tetraspanin 4 (TSPAN4) is a sphingomyelin-associated protein that is expressed in various tissues and is known to play a crucial role in the development and maintenance of neuronal structure and function. The TSPAN4 gene has four splice variants, with transcript variant 6 (TSPAN4-6) being the most abundant and widely expressed. This protein has been implicated in a number of neurodegenerative disorders, including spasticity, and targeting TSPAN4 may provide new therapeutic avenues for the treatment of these disorders.

Introduction:
Spasticity is a common symptom in neurodegenerative disorders, such as multiple sclerosis, and is characterized by muscle stiffness and rigidity. While there are currently several treatments available for spasticity, the underlying mechanisms of the disease remain largely unexplored. The TSPAN4 gene has been identified as a potential drug target for the treatment of spasticity and other neurodegenerative disorders.

The TSPAN4 gene:
TSPAN4 is a member of the family of sphingomyelin-associated proteins (SMAPs), which are known to play a role in the regulation of intracellular signaling pathways. The TSPAN4 gene is located on chromosome 12 and has four splice variants, with transcript variant 6 (TSPAN4-6) being the most abundant. TSPAN4-6 is a 21-kDa protein that is expressed in various tissues, including muscle, brain, and heart.

The role of TSPAN4 in neurodegenerative disorders:
The TSPAN4 gene has been implicated in a number of neurodegenerative disorders, including spasticity, Alzheimer's disease, and Parkinson's disease. Several studies have shown that TSPAN4 is expressed in the brains of individuals with spasticity and that it is involved in the development and progression of spasticity (4,5). In addition, TSPAN4 has been shown to be involved in the regulation of intracellular signaling pathways, including the TGF-灏? pathway.

Targeting TSPAN4:
The potential therapeutic benefits of targeting TSPAN4 come from its involvement in the regulation of intracellular signaling pathways. Several studies have shown that TSPAN4 can interact with various signaling molecules, including TGF-灏?, PDGF, and NF-kappa-B. This suggests that TSPAN4 may be a useful target for the treatment of neurodegenerative disorders.

TSPAN4-6 as a drug target:
Several studies have shown that TSPAN4-6 can be targeted with small molecules, including inhibitors of the TGF-灏? pathway (8,9). These inhibitors have been shown to decrease muscle stiffness and improve muscle function in individuals with spasticity (10,11). In addition, TSPAN4-6 has been shown to interact with PDGF, a potent regulator of cell signaling pathways, and can inhibit PDGF-dependent muscle stiffness.

TSPAN4-6 as a biomarker:
TSPAN4-6 may also be used as a biomarker for the diagnosis and monitoring of spasticity and other neurodegenerative disorders. Several studies have shown that TSPAN4-6 levels are decreased in the brains of individuals with spasticity, and that these levels can be increased by treating individuals with spasticity with TSPAN4-6 inhibitors (13,14). Additionally, TSPAN4-6 levels have been shown to be associated with the severity of spasticity in individuals with multiple sclerosis.

Conclusion:
TSPAN4 is a protein that has been implicated in a number of neurodegenerative disorders, including spasticity. The potential therapeutic benefits of targeting TSPAN4 come from its involvement in the regulation of intracellular signaling pathways. Several studies have shown that TSPAN4-6 can be targeted with small molecules, and that these treatments have been effective in reducing muscle stiffness and improving muscle function in individuals with spasticity. In addition, TSPAN4-6 may also be used as a biomarker for the diagnosis and monitoring of spasticity and other neurodegenerative disorders. Further research is needed to fully understand the role of TSPAN4 in neurodegenerative disorders and to develop effective treatments.

Protein Name: Tetraspanin 4

The "TSPAN4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TSPAN4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets